Colin Hessel

7.8k total citations · 1 hit paper
25 papers, 2.1k citations indexed

About

Colin Hessel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Colin Hessel has authored 25 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Colin Hessel's work include Renal cell carcinoma treatment (9 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Renal and related cancers (7 papers). Colin Hessel is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Renal and related cancers (7 papers). Colin Hessel collaborates with scholars based in United States, France and United Kingdom. Colin Hessel's co-authors include Steven I. Sherman, Patrick Schöffski, Michael C. Kreißl, Barbara Jarząb, Manisha H. Shah, Douglas W. Ball, Marcia S. Brose, Lisa Licitra, Yifah Yaron and Haythem Ali and has published in prestigious journals such as Journal of Clinical Oncology, PEDIATRICS and Cancer Research.

In The Last Decade

Colin Hessel

25 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Colin Hessel United States	14	711	596	595	524	420	25	2.1k
Seymour Grufferman United States	28	521 0.7×	862 1.4×	424 0.7×	220 0.4×	251 0.6×	73	2.9k
Eva Segelov Australia	25	526 0.7×	1.4k 2.4×	419 0.7×	88 0.2×	375 0.9×	158	2.4k
Paul Harden United Kingdom	30	863 1.2×	1.1k 1.9×	386 0.6×	70 0.1×	473 1.1×	96	3.4k
Oka M Japan	23	311 0.4×	460 0.8×	266 0.4×	59 0.1×	431 1.0×	125	1.8k
Claire Cropet France	23	298 0.4×	1.8k 3.0×	1.4k 2.4×	68 0.1×	556 1.3×	95	3.2k
Quyen D. Chu United States	25	333 0.5×	1.0k 1.7×	345 0.6×	101 0.2×	350 0.8×	134	2.4k
Cheng‐Maw Ho Taiwan	22	372 0.5×	450 0.8×	239 0.4×	70 0.1×	182 0.4×	121	1.6k
Massimiliano Fambrini Italy	26	417 0.6×	432 0.7×	173 0.3×	157 0.3×	203 0.5×	120	3.3k
Marta M. Gilson United States	19	274 0.4×	2.3k 3.9×	779 1.3×	55 0.1×	404 1.0×	33	3.5k
Arnold J. Markowitz United States	27	237 0.3×	1.5k 2.5×	541 0.9×	99 0.2×	339 0.8×	87	2.6k

Countries citing papers authored by Colin Hessel

Since Specialization

Citations

This map shows the geographic impact of Colin Hessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Hessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Hessel more than expected).

Fields of papers citing papers by Colin Hessel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin Hessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Hessel. The network helps show where Colin Hessel may publish in the future.

Co-authorship network of co-authors of Colin Hessel

This figure shows the co-authorship network connecting the top 25 collaborators of Colin Hessel. A scholar is included among the top collaborators of Colin Hessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin Hessel. Colin Hessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frentzas, Sophia, G. Thomas Budd, Catherine Shannon, et al.. (2024). Abstract PO1-04-01: Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients. Cancer Research. 84(9_Supplement). PO1–4. 3 indexed citations

Ellingson, Benjamin M., Akifumi Hagiwara, Nicholas S. Cho, et al.. (2023). Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. Clinical Cancer Research. 29(20). 4186–4195. 5 indexed citations

Shen, John Paul, Russell K. Pachynski, Luke T. Nordquist, et al.. (2023). 1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S974–S975. 11 indexed citations

George, Daniel J., Colin Hessel, Susan Halabi, et al.. (2019). Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. The Oncologist. 24(11). 1497–1501. 20 indexed citations

Choueiri, Toni K., Colin Hessel, Susan Halabi, et al.. (2018). Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European Journal of Cancer. 94. 115–125. 267 indexed citations

Abou‐Alfa, Ghassan K., Tim Meyer, Ann‐Lii Cheng, et al.. (2018). Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.. Journal of Clinical Oncology. 36(15_suppl). 4019–4019. 8 indexed citations

George, Daniel J., Colin Hessel, Susan Halabi, et al.. (2018). Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. Journal of Clinical Oncology. 36(6_suppl). 582–582. 7 indexed citations

Maia, Manuel Caitano, Neeraj Agarwal, Bradley A. McGregor, et al.. (2018). Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. Journal of Clinical Oncology. 36(5_suppl). TPS42–TPS42. 4 indexed citations

Choueiri, Toni K., Colin Hessel, Susan Halabi, et al.. (2017). Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). Annals of Oncology. 28. v623–v623. 12 indexed citations

10.

Ellingson, Benjamin M., Robert J. Harris, Davis C. Woodworth, et al.. (2016). Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro-Oncology. 19(1). 89–98. 55 indexed citations

11.

Choueiri, Toni K., Thomas Powles, Bernard Escudier, et al.. (2016). Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 34(15_suppl). 4506–4506. 2 indexed citations

12.

Schlumberger, Martin, Rossella Elisei, Stefan Müller, et al.. (2015). Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.. Journal of Clinical Oncology. 33(15_suppl). 6012–6012. 23 indexed citations

13.

Elisei, Rossella, Martin Schlumberger, Stefan Müller, et al.. (2013). Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology. 31(29). 3639–3646. 850 indexed citations breakdown →

14.

Schöffski, Patrick, Rossella Elisei, Stefan Müller, et al.. (2012). An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. Journal of Clinical Oncology. 30(15_suppl). 5508–5508. 68 indexed citations

15.

Piedra, Pedro A., Manjusha Gaglani, Mark W. Riggs, et al.. (2005). Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial. PEDIATRICS. 116(3). e397–e407. 81 indexed citations

16.

Bergen, Randy, Steve Black, Henry R. Shinefield, et al.. (2004). Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. The Pediatric Infectious Disease Journal. 23(2). 138–144. 112 indexed citations

17.

Belshe, Robert B., Kristin L. Nichol, Henry R. Shinefield, et al.. (2004). Safety, Efficacy, and Effectiveness of Live, Attenuated, Cold‐Adapted Influenza Vaccine in an Indicated Population Aged 5–49 Years. Clinical Infectious Diseases. 39(7). 920–927. 78 indexed citations

18.

Piedra, Pedro A., Manjusha Gaglani, Claudia A. Kozinetz, et al.. (2004). Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 23(13). 1540–1548. 219 indexed citations

19.

Redding, Gregory J., Robert Walker, Colin Hessel, et al.. (2002). Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. The Pediatric Infectious Disease Journal. 21(1). 44–48. 57 indexed citations

20.

Clark, Florence, Ruth Zemke, Jeanne Jackson, et al.. (1997). Occupational therapy for independent-living older adults. A randomized controlled trial.. PubMed. 278(16). 1321–6. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact